The only thing that matters is data. His opinion is worth trading around. Same with that Fassel guy (who I actually consider a semi-pumper) Whatever. 1yr price target 7.50+ OR 2.50-
He also says this "The existence of other, perhaps superior, AD drugs does not undercut the value of Star Scientific at all. The anti-inflammaging effects of anatabine are, as I’ve explained on numerous occasions, bigger even than a complete AD cure."
But yes we do still need to see peer-reviewed research first before drawing any serious conclusions about any of this
He is also saying that this does not harm the prospects for anatabine, because: 1) a combination of three drugs, one of which is anatabine, may be the best treatment (each works by a different mechanism and people are biologically very different from one another; 2) anatabine seems to improve a hugh range of conditions.
Market Data 
Markets 
AI
